# Iterum Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iterum-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Dublin, Ireland
- Website: www.iterumtx.com
- Total disclosed funding: $105M
- Latest round: Series B (May 19, 2017)
- Investors on record: 9

## About

Based in Ireland, Iterum Therapeutics plc focuses on developing innovative anti-infective therapies to combat multi-drug resistant bacterial infections, addressing critical public health needs with novel solutions.Founded in 2015 in Dublin, Ireland, Iterum Therapeutics plc specializes in anti-infective therapies. The company has undergone strategic fundraising, including a recent Private Placement/Follow on worth USD 35.00 mn, raising a total of USD 35.00 mn to date. The CEO is Corey Fishman, and the company has completed 8 deals as of February 2021.Iterum Therapeutics plc specializes in developing innovative anti-infective therapies, particularly focusing on the novel antibiotic sulopenem, designed for both oral and intravenous use. It targets multi-drug resistant gram-negative infections, offering new treatment options for healthcare providers across the United States and selected international markets.In the most recent fiscal year, 2021, Iterum Therapeutics plc reported zero revenue with an EBITDA of USD -18.34 mn. The company's revenue model is centered around B2B transactions with healthcare providers, delivering its antibiotic therapies to combat antibiotic-resistant infections.Iterum Therapeutics aims to launch new products, including expanded indications for sulopenem, and is targeting growth in both U.S. and international markets. Recent funding from the Private Placement will support these initiatives, facilitating further market penetration and product development efforts.

## Funding rounds

- Series B, May 19, 2017, $65M — Domain Associates, Frazier Healthcare Partners, Sofinnova Investments, Canaan Partners, New Leaf Venture Partners, Bay City Capital, Arix Bioscience, Advent Life Sciences, Pivotal Life Sciences
- Series A, Mar 24, 2016, $40M — Frazier Healthcare Partners, Sofinnova Investments, Canaan Partners, New Leaf Venture Partners

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series A, Series B
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series A, Series B
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series B
- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series B
- Arix Bioscience (https://capitalatlas.ai/funds/arix-bioscience) — Series B
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series B
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Series B